Currently, the combination of KRASG12C inhibitors with EGFR inhibitors is being studied in patients with chemotherapy-refractory KRASG12C-mutant metastatic colorectal cancer, and the addition of EGFR inhibitors to KRASG12C inhibitors has been shown to greatly increase the response rate of KRASG12C inhibitors (115, 117, 118). The gene discussed is EGFR; the disease is metastatic colorectal cancer.